38. (new) A vaccine comprising a chimeric non-segmented negative strand RNA virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of said virus and a pharmaceutically acceptable carrier.

39. (new) The vaccine of claim 38 wherein the non-segmented virus is selected from the members of the Paramyxoviridae family.

40. (new) The vaccine of claim 39 wherein the Paramyxoviridae family member is Respiratory Syncytial Virus or parainfluenza.

REMARKS

According to the Office Action mailed March 11, 2002, claims 1-35 were pending in this application. New claims 36-40 have been added to more distinctly point out and claim what Applicants consider as the invention. The new claims 36-40 are fully supported by the instant specification, see, *e.g.*, the table below, and do not represent new subject matter. Claims 1-40, therefore, will be pending upon entry of the present amendments.

CLAIMS	SUPPORT IN SPECIFICATION
36	page 15, lines 27-28
37	section 8.1; page 51, line 10 to page 53, line 5
38-40	page 2, lines 14-23; page 14, lines 1-8; page 22, lines 22-25; and page 30, lines 13-21

The Examiner has required restriction of the claims under 35 U.S.C. § 121 to one of the following inventions:

I. Claims 1-12, drawn to isolated respiratory syncytial virus (RSV) with a M2-2, SH, NS1, or NS2 gene mutation classified in class 435, subclass 236.

II. Claim 13, drawn to isolated RSV with a M2-1 gene mutation, classified in class 435, subclass 236.